Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1)

NCT04980833 · tracked via the Priya Life Science Spain tracker

Sponsor

Novartis Pharmaceuticals

Phase

Phase 2

Started

2022-01-27

Last updated

2026-04-02

Condition(s) studied

PIK3CA-related Overgrowth Spectrum (PROS)

Investigational drug(s) / intervention(s)

Alpelisib →

Alpelisib: Participant's treatment plan has been established by the treating physician, within the global compassionate use framework. Doses permitted are 50, 125, 200 and 250 mg.

Study summary

This is a prospective interventional Phase II multi center study, open label, preceded by a retrospective non-interventional period, to assess the long-term safety and efficacy of alpelisib, in pediatric and adult participants with PROS.

Eligibility

Sex

ALL

Min age

2 Years

Max age

100 Years

Healthy volunteers

Inclusion Criteria: * Participants who had previously participated in the study EPIK-P1. * Signed informed consent form and assent (when applicable) from the participant, parent, or guardian must be obtained prior to any study related screening procedures being performed. * Participant is treated with at least one dose of alpelisib after the EPIK-P1 study data cut- off date of 09-Mar-2020. Exclusion Criteria: For participants in the retrospective period \- All EPIK-P1 participants who permanently discontinued the investigational drug on or prior to the cut-off date 09-Mar-2020. For participants in the prospective period * Previous alpelisib treatment discontinuation (after 09-Mar-2020) due to any of the following adverse events: * Grade 4 skin and subcutaneous tissue disorders * Stevens-Johnson-Syndrome (SJS)/ Toxic Epidermal Necrolysis (TEN) or other SJS/TEN-like severe skin reactions (any grade) * Grade 4 hyperglycemia without confounding factors * Pneumonitis (any grade) * Grade 4 stomatitis * Grade 4 pancreatitis * Recurrent grade 4 thrombocytopenia * Grade 3 or 4 serum creatinine increase * Grade 4 isolated total bilirubin elevation * Recurrent grade 3 or 4 QT interval corrected by Fridericia's formula prolongation (\>500 ms or \>60 ms change from baseline) * Known impairment of GI function due to concomitant disease that may significantly alter the absorption of the study drug (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection) at time of informed consent. * Participant with uncontrolled diabetes mellitus (Type I or II) at time of informed consent. Other inclusion/exclusion criteria may apply

Primary outcome measure(s)

Prospective period only: Proportion of participants with new or worsening grade ≥3 treatment emergent adverse events (AEs) — From date of first interventional dose administration in the prospective period (Day 1) to 30 days after last dose of study drug, assessed up to 5 years.
Incidence of new or worsening grade ≥3 treatment emergent AEs (by system organ class and preferred term)

Trial sites (6)

Facility	City	Region
Boston Childrens Hospital	Boston	Massachusetts
Novartis Investigative Site	Dijon	France
Novartis Investigative Site	Montpellier	France
Novartis Investigative Site	Paris	France
Novartis Investigative Site	Dublin	Ireland
Novartis Investigative Site	Madrid	Spain

More Novartis Pharmaceuticals trials in Spain

Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease Active, not recruiting

A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor. Active, not recruiting

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Active, not recruiting

A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS) Active, not recruiting

Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer Active, not recruiting

Other trials for the same condition

A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study) Recruiting

Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum Active, not recruiting

EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS) Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04980833 on ClinicalTrials.gov ↗ ← All trials in Spain